Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Barth, DA; Riedl, JM; Posch, F; Smolle, MA; Kasparek, AK; Niedrist, T; Szkandera, J; Stöger, H; Pichler, M; Stotz, M; Gerger, A.
Critical evaluation of platelet size as a prognostic biomarker in colorectal cancer across multiple treatment settings: a retrospective cohort study.
Clin Transl Oncol. 2019; 21(8):1034-1043
Doi: 10.1007/s12094-019-02037-7
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Barth Dominik Andreas
- Stotz Michael
- Co-Autor*innen der Med Uni Graz
- Gerger Armin
- Kasparek Anne-Katrin
- Niedrist Tobias
- Pichler Martin
- Posch Florian
- Riedl Jakob
- Smolle Maria Anna
- Stöger Herbert
- Szkandera Joanna
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The role of mean platelet volume (MPV) as a predictor of outcomes in various cancer entities including colorectal cancer (CRC) has already been analyzed. However, data on the prognostic and predictive value of MPV in CRC over multiple lines of systemic therapy are missing. In this retrospective single-center cohort study, 690 patients with UICC stage II, III or IV CRC receiving adjuvant and/or palliative chemotherapy were included. Primary endpoints in the adjuvant, palliative and best supportive care (BSC) setting were 3-year recurrence-free survival (RFS), 6-months progression-free survival (PFS), and 6-months overall survival (OS), respectively. Kaplan-Meier estimators, log-rank tests, and uni- and multivariable Cox models were used to analyze RFS, PFS and OS. A cut-off defining patients with low MPV was chosen empirically at the 25th percentile of the MPV distribution in the respective treatment setting. Three-year RFS was 76%. Median 6-month PFS estimates in 1st, 2nd and 3rd line therapy were 59, 37 and 27%, respectively. Median 6-month OS in BSC was 31%. Small platelets as indicated by low MPV did not predict for shorter RFS. In the first 3 palliative treatment lines a consistent association between low MPV and decreased 6-month PFS was not observed. In the BSC setting, patients with low MPV had numerically but not significantly shorter OS. Higher MPV levels did not consistently predict for ORR or DCR across the first 3 palliative treatment lines. Small platelets are not predicting CRC outcomes, and thus are hardly useful for influencing clinical decision making.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Antineoplastic Combined Chemotherapy Protocols - therapeutic use
- Biomarkers, Tumor -
- Blood Platelets - drug effects
- Blood Platelets - pathology
- Colorectal Neoplasms - blood
- Colorectal Neoplasms - drug therapy
- Colorectal Neoplasms - pathology
- Female -
- Follow-Up Studies -
- Humans -
- Male -
- Mean Platelet Volume - statistics & numerical data
- Middle Aged -
- Neoplasm Recurrence, Local - blood
- Neoplasm Recurrence, Local - drug therapy
- Neoplasm Recurrence, Local - pathology
- Prognosis -
- Retrospective Studies -
- Survival Rate -
- Find related publications in this database (Keywords)
- Mean platelet volume
- Biomarker
- Colorectal cancer
- Adjuvant chemotherapy
- Palliative chemotherapy